{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T02:42:27Z","timestamp":1760496147633,"version":"build-2065373602"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T00:00:00Z","timestamp":1760400000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T00:00:00Z","timestamp":1760400000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100020337","name":"Springworks Therapeutics","doi-asserted-by":"publisher","award":["Springworks Therapeutics"],"award-info":[{"award-number":["Springworks Therapeutics"]}],"id":[{"id":"10.13039\/100020337","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Desmoid tumors (DT) are rare, locally aggressive soft tissue tumors that pose considerable diagnostic and treatment challenges, and may negatively impact patients\u2019 overall quality of life (QoL). This analysis examines three aspects of the real-world patient experience with DT: (1) demographics and disease characteristics, (2) the journey from initial signs and symptoms to definitive DT diagnosis and treatment, and (3) QoL. The ongoing Desmoid Tumor Research Foundation (DTRF) Patient Registry and Natural History Study (NHS) examines patient-reported survey data to characterize the real-world nature and impact of DT, including clinical history, prior and current treatment, and QoL. The GOunder\/DTRF Desmoid Symptom\/Impact Scale (GODDESS<jats:sup>\u00a9<\/jats:sup>) patient-reported outcomes tool was used to assess DT-specific QoL, such as pain, fatigue, physical functioning, sleep, and emotional impact.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>This analysis was performed on data collected by the DTRF NHS between September 2017 and August 2023 using the most recent survey submitted by participants, including clinical characteristics, treatment experience, and patient-reported outcomes (PROs) data assessed by the GODDESS tool. Where applicable, continuous variables were assessed using descriptive statistics. Between-group proportions were compared using Pearson\u2019s chi-square test or Fisher\u2019s exact test. Analysis of variance was performed to assess the differences in mean time to diagnosis and mean scores of GODDESS Desmoid Tumor Symptom Scale (DTSS) and Desmoid Tumor Impact Scale (DTIS) domains and items across the subgroups of age, current tumor status, and tumor location where appropriate.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Surveys were completed by 399 participants between September 2017 and August 2023. The median age of participants was 38 years; most were female (72%, 288\/399), White (84%, 334\/399), or resided in North America (86%, 345\/399). Signs and symptoms reported at diagnosis included an unexplained bump (60%, 238\/399), pain (57%, 226\/399), and fatigue (14%, 54\/399). A total of 162 participants (41%, 162\/399) reported a prior misdiagnosis. Surgical procedures were the most common first-line therapy in those reporting multiple treatments for DT (59%, 74\/126), followed by chemotherapy (24%, 30\/126). Among 126 participants who reported a prior misdiagnosis and history of surgery for DT, 46% (58\/126) reported having received surgery before a definitive DT diagnosis. For those undergoing surgery (any line) post-diagnosis, tumor recurrence was common (63%, 103\/163). Participants with the presence of DT at survey completion reported significantly worse scores for pain, extra-abdominal symptoms, fatigue, physical functioning, and sleep in comparison to those without the current presence of a DT (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.05).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Patients with DT can experience a high disease burden. Misdiagnosis can lead to unnecessary surgery, potentially delaying an appropriate treatment for DT, and tumor regrowth that can contribute to impaired QoL after surgery. The analysis of NHS data presented in this manuscript highlights real-world experiences of patients with DT and underscores the need for patient-centric treatment strategies and outcomes.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s13023-025-04021-7","type":"journal-article","created":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T15:46:37Z","timestamp":1760456797000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The impact of desmoid tumors: insights from the Desmoid Tumor Research Foundation Natural History Study, 2017\u20132023"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-1786-370X","authenticated-orcid":false,"given":"Amanda","family":"Lucas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-7150-2983","authenticated-orcid":false,"given":"Shengfan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-5786-0233","authenticated-orcid":false,"given":"Lynne","family":"Hernandez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8909-5293","authenticated-orcid":false,"given":"Timothy","family":"Bell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6126-7353","authenticated-orcid":false,"given":"Ana B.","family":"Oton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8771-6401","authenticated-orcid":false,"given":"Kelly","family":"Mercier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,14]]},"reference":[{"issue":"4","key":"4021_CR1","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1097\/CCO.0000000000000374","volume":"29","author":"N Penel","year":"2017","unstructured":"Penel N, Chibon F, Salas S. Adult desmoid tumors: biology, management and ongoing trials. Curr Opin Oncol. 2017;29(4):268\u201374.","journal-title":"Curr Opin Oncol"},{"issue":"2","key":"4021_CR2","doi-asserted-by":"publisher","first-page":"70","DOI":"10.32074\/1591-951X-213","volume":"113","author":"M Sbaraglia","year":"2021","unstructured":"Sbaraglia M, Bellan E, Dei Tos AP. The 2020 WHO classification of soft tissue tumours: news and perspectives. Pathologica. 2021;113(2):70\u201384.","journal-title":"Pathologica"},{"issue":"9","key":"4021_CR3","doi-asserted-by":"publisher","first-page":"3697","DOI":"10.1007\/s12325-023-02592-0","volume":"40","author":"M Bektas","year":"2023","unstructured":"Bektas M, Bell T, Khan S, et al. Desmoid tumors: a comprehensive review. Adv Ther. 2023;40(9):3697\u2013722.","journal-title":"Adv Ther"},{"issue":"10","key":"4021_CR4","doi-asserted-by":"publisher","first-page":"2399","DOI":"10.1093\/annonc\/mdx323","volume":"28","author":"B Kasper","year":"2017","unstructured":"Kasper B, Baumgarten C, Garcia J, et al. An update on the management of sporadic desmoid-type fibromatosis: a European consensus initiative between sarcoma patients EuroNet (SPAEN) and European organization for research and treatment of cancer (EORTC)\/soft tissue and bone sarcoma group (STBSG). Ann Oncol. 2017;28(10):2399\u2013408.","journal-title":"Ann Oncol"},{"issue":"1","key":"4021_CR5","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.ocl.2005.08.004","volume":"37","author":"HS Hosalkar","year":"2006","unstructured":"Hosalkar HS, Fox EJ, Delaney T, Torbert JT, Ogilvie CM, Lackman RD. Desmoid tumors and current status of management. Orthop Clin North Am. 2006;37(1):53\u201363.","journal-title":"Orthop Clin North Am"},{"issue":"3","key":"4021_CR6","first-page":"965","volume":"27","author":"O Husson","year":"2019","unstructured":"Husson O, Younger E, Dunlop A, et al. Desmoid fibromatosis through the patients\u2019 eyes: time to change the focus and organisation of care? Support Care Cancer. 2019;27(3):965\u201380.","journal-title":"Support Care Cancer"},{"key":"4021_CR7","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/978-94-007-1685-8_2","volume-title":"Desmoid Tumors","author":"A Constantinidou","year":"2012","unstructured":"Constantinidou A, Scurr M, Judson I, Litchman C. Clinical presentation of desmoid tumors. In: Litchman C, editor. Desmoid Tumors. Netherlands: Springer; 2012. p. 5\u201316."},{"key":"4021_CR8","doi-asserted-by":"publisher","first-page":"203636131988097","DOI":"10.1177\/2036361319880978","volume":"11","author":"KA Mercier","year":"2019","unstructured":"Mercier KA, Walsh DM. The initiation, design, and establishment of the desmoid tumor research foundation patient registry and natural history study. Rare Tumors. 2019;11:2036361319880978.","journal-title":"Rare Tumors"},{"issue":"10","key":"4021_CR9","doi-asserted-by":"publisher","first-page":"2861","DOI":"10.1007\/s11136-023-03445-7","volume":"32","author":"MM Gounder","year":"2023","unstructured":"Gounder MM, Atkinson TM, Bell T, et al. GOunder\/Desmoid tumor research foundation desmoid symptom\/impact scale (GODDESS(\u00a9)): psychometric properties and clinically meaningful thresholds as assessed in the phase 3 DeFi randomized controlled clinical trial. Qual Life Res. 2023;32(10):2861\u201373.","journal-title":"Qual Life Res"},{"key":"4021_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.canep.2022.102114","volume":"77","author":"M Anneberg","year":"2022","unstructured":"Anneberg M, Svane HML, Fryzek J, et al. The epidemiology of desmoid tumors in Denmark. Cancer Epidemiol. 2022;77:102114.","journal-title":"Cancer Epidemiol"},{"issue":"6","key":"4021_CR11","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1016\/j.mayocp.2017.02.012","volume":"92","author":"KM Skubitz","year":"2017","unstructured":"Skubitz KM. Biology and treatment of aggressive fibromatosis or desmoid tumor. Mayo Clin Proc. 2017;92(6):947\u201364.","journal-title":"Mayo Clin Proc"},{"issue":"16","key":"4021_CR12","doi-asserted-by":"publisher","first-page":"3027","DOI":"10.1002\/cncr.34332","volume":"128","author":"RF Riedel","year":"2022","unstructured":"Riedel RF, Agulnik M. Evolving strategies for management of desmoid tumor. Cancer. 2022;128(16):3027\u201340.","journal-title":"Cancer"},{"key":"4021_CR13","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.ejca.2016.02.008","volume":"58","author":"N Penel","year":"2016","unstructured":"Penel N, Coindre JM, Bonvalot S, et al. Management of desmoid tumours: a nationwide survey of labelled reference centre networks in France. Eur J Cancer. 2016;58:90\u20136.","journal-title":"Eur J Cancer"},{"key":"4021_CR14","unstructured":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Soft Tissue Sarcoma V.1.2025; May 2, 2025 \u00a9 National Comprehensive Cancer Network, Inc. 2025. All rights reserved. Accessed June 13, 2025. To view the most recent and complete version of the guideline, go online to www.NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way."},{"issue":"2","key":"4021_CR15","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1111\/j.1365-2559.2012.04355.x","volume":"62","author":"S Huss","year":"2013","unstructured":"Huss S, Nehles J, Binot E, et al. \u03b2-catenin (CTNNB1) mutations and clinicopathological features of mesenteric desmoid-type fibromatosis. Histopathology. 2013;62(2):294\u2013304.","journal-title":"Histopathology"},{"issue":"8","key":"4021_CR16","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1001\/jamaoncol.2024.1805","volume":"10","author":"B Kasper","year":"2024","unstructured":"Kasper B, Baldini EH, Bonvalot S, et al. Current management of desmoid tumors: a review. JAMA Oncol. 2024;10(8):1121\u20138.","journal-title":"JAMA Oncol"},{"issue":"6","key":"4021_CR17","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1080\/14737167.2023.2203915","volume":"23","author":"MM Fernandez","year":"2023","unstructured":"Fernandez MM, Bell T, Tumminello B, Khan S, Zhou S, Oton AB. Disease and economic burden of surgery in desmoid tumors: a review. Expert Rev Pharmacoecon Outcomes Res. 2023;23(6):607\u201318.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"4021_CR18","unstructured":"SpringWorks, Therapeutics. Inc. OGSIVEO\u00ae (nirogacestat). Full Prescribing Information. 2023."},{"issue":"10","key":"4021_CR19","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1056\/NEJMoa2210140","volume":"388","author":"M Gounder","year":"2023","unstructured":"Gounder M, Ratan R, Alcindor T, et al. Nirogacestat, a gamma-secretase inhibitor for desmoid tumors. N Engl J Med. 2023;388(10):898\u2013912.","journal-title":"N Engl J Med"},{"issue":"3","key":"4021_CR20","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1002\/cncr.32555","volume":"126","author":"MM Gounder","year":"2020","unstructured":"Gounder MM, Maddux L, Paty J, Atkinson TM. Prospective development of a patient-reported outcomes instrument for desmoid tumors or aggressive fibromatosis. Cancer. 2020;126(3):531\u20139.","journal-title":"Cancer"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-04021-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-025-04021-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-04021-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T02:06:58Z","timestamp":1760494018000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-025-04021-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,14]]},"references-count":20,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4021"],"URL":"https:\/\/doi.org\/10.1186\/s13023-025-04021-7","relation":{},"ISSN":["1750-1172"],"issn-type":[{"type":"electronic","value":"1750-1172"}],"subject":[],"published":{"date-parts":[[2025,10,14]]},"assertion":[{"value":"30 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical oversight and approval for the DTRF NHS was obtained from the North Star Review Board (NB100030). The DTRF NHS study was conducted in accordance with Good Clinical Practices, following guidance from ICH GCP and the United States CFR. The study was also performed in accordance with the Helsinki Declaration of 1964 and its later amendments. Informed consent was obtained electronically as part of the DTRF NHS registration process.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"AL, LH, and KM are employees of DTRF and received a grant from SpringWorks Therapeutics to support this project. TB, SZ, and AO are employees of SpringWorks Therapeutics.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"515"}}